Physician profile
Robert Polofsky
NPI 1902830557
$11,103.18
in general payments reported to CMS, 2019-2025
58 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,087 · 2020: $1,314 · 2021: $1,980 · 2022: $1,964 · 2023: $1,280 · 2024: $1,210 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,659 · Gift: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,659.14 |
| Gift | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,289.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $849.91 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $699.06 | 2019-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $618.39 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $616.73 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $566.03 | 2019-2025 | |
| Amarin Pharma, INC. | $480.62 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $443.48 | 2021-2025 | |
| Esperion Therapeutics, INC. | $421.77 | 2021-2024 | Nexletol, Nexlizet |
| Xeris Pharmaceuticals, INC. | $406.59 | 2021-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Glaxosmithkline, LLC. | $377.85 | 2019-2025 | Trelegy Ellipta |
| Sekisui Diagnostics LLC | $370.00 | 2022-2025 | |
| Abbvie INC. | $357.71 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $325.80 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $296.17 | 2019-2024 | Gattex |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Polofsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.